CUE PE Ratio & Valuation,Is CUE Overvalued

CUE Relative Valuation

CUE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CUE is overvalued; if below, it's undervalued.

Historical Valuation

Cue Biopharma Inc (CUE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.15 is considered Undervalued compared with the five-year average of -3.57. The fair price of Cue Biopharma Inc (CUE) is between 0.72 to 1.34 according to relative valuation methord. Compared to the current price of 0.46 USD , Cue Biopharma Inc is Undervalued By 36.03%.

Relative Value

Fair Zone

0.72-1.34

Current Price：0.46

36.03%

Undervalued

-1.02

0.00

EV/EBITDA

Cue Biopharma Inc. (CUE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.60. The thresholds are as follows: Strongly Undervalued below -6.82, Undervalued between -6.82 and -4.21, Fairly Valued between 1.01 and -4.21, Overvalued between 1.01 and 3.62, and Strongly Overvalued above 3.62. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.54

EV/EBIT

Cue Biopharma Inc. (CUE) has a current EV/EBIT of -0.54. The 5-year average EV/EBIT is -2.44. The thresholds are as follows: Strongly Undervalued below -6.82, Undervalued between -6.82 and -4.63, Fairly Valued between -0.25 and -4.63, Overvalued between -0.25 and 1.93, and Strongly Overvalued above 1.93. The current Forward EV/EBIT of -0.54 falls within the Historic Trend Line -Fairly Valued range.

4.15

Cue Biopharma Inc. (CUE) has a current PS of 4.15. The 5-year average PS is 44.29. The thresholds are as follows: Strongly Undervalued below -70.07, Undervalued between -70.07 and -12.89, Fairly Valued between 101.46 and -12.89, Overvalued between 101.46 and 158.64, and Strongly Overvalued above 158.64. The current Forward PS of 4.15 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Cue Biopharma Inc. (CUE) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.80. The thresholds are as follows: Strongly Undervalued below -9.42, Undervalued between -9.42 and -6.11, Fairly Valued between 0.51 and -6.11, Overvalued between 0.51 and 3.82, and Strongly Overvalued above 3.82. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.92

P/FCF

Cue Biopharma Inc. (CUE) has a current P/FCF of -0.92. The 5-year average P/FCF is -2.20. The thresholds are as follows: Strongly Undervalued below -9.60, Undervalued between -9.60 and -5.90, Fairly Valued between 1.50 and -5.90, Overvalued between 1.50 and 5.19, and Strongly Overvalued above 5.19. The current Forward P/FCF of -0.92 falls within the Historic Trend Line -Fairly Valued range.

Cue Biopharma Inc (CUE) has a current Price-to-Book (P/B) ratio of 2.83. Compared to its 3-year average P/B ratio of 3.04 , the current P/B ratio is approximately -6.88% higher. Relative to its 5-year average P/B ratio of 3.43, the current P/B ratio is about -17.57% higher. Cue Biopharma Inc (CUE) has a Forward Free Cash Flow (FCF) yield of approximately -77.75%. Compared to its 3-year average FCF yield of -49.81%, the current FCF yield is approximately 56.09% lower. Relative to its 5-year average FCF yield of -37.79% , the current FCF yield is about 105.71% lower.

2.70

P/B

Median3y

3.04

Median5y

3.43

-77.75

FCF Yield

Median3y

-49.81

Median5y

-37.79

Competitors Valuation Multiple

The average P/S ratio for CUE's competitors is 0.00, providing a benchmark for relative valuation. Cue Biopharma Inc Corp (CUE) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -35.58%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CUE decreased by 57.57% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -259.59 to -346.58.

The secondary factor is the Revenue Growth, contributed -35.58%to the performance.

Overall, the performance of CUE in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-35.58%

3.34M → 2.15M

Revenue Growth

33.51%

-259.59 → -346.58

Margin Expansion

-55.50%

-2.37 → -1.05

P/E Change

-57.57%

1.09 → 0.46

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Cue Biopharma Inc (CUE) currently overvalued or undervalued?

What is Cue Biopharma Inc (CUE) fair value?

CUE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cue Biopharma Inc (CUE) is between 0.72 to 1.34 according to relative valuation methord.

How does CUE's valuation metrics compare to the industry average?

What is the current P/B ratio for Cue Biopharma Inc (CUE) as of Dec 16 2025?

As of Dec 16 2025, Cue Biopharma Inc (CUE) has a P/B ratio of 2.83. This indicates that the market values CUE at 2.83 times its book value.

What is the current FCF Yield for Cue Biopharma Inc (CUE) as of Dec 16 2025?

As of Dec 16 2025, Cue Biopharma Inc (CUE) has a FCF Yield of -77.75%. This means that for every dollar of Cue Biopharma Inc’s market capitalization, the company generates -77.75 cents in free cash flow.

What is the current Forward P/E ratio for Cue Biopharma Inc (CUE) as of Dec 16 2025?

As of Dec 16 2025, Cue Biopharma Inc (CUE) has a Forward P/E ratio of -1.07. This means the market is willing to pay $-1.07 for every dollar of Cue Biopharma Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cue Biopharma Inc (CUE) as of Dec 16 2025?

As of Dec 16 2025, Cue Biopharma Inc (CUE) has a Forward P/S ratio of 4.15. This means the market is valuing CUE at $4.15 for every dollar of expected revenue over the next 12 months.

CUE Valuation